In conclusion, low TRIM6 expression in patients with AML is closely associated with poor overall survival, potentially linked to immune cell infiltration and the regulation of the PI3K/AKT signaling pathway, and is involved in proliferation, apoptosis, and cell cycle processes, making it a potentially important prognostic biomarker for AML. Here, TRIM6 is linked to acute myeloid leukemia.